Prostate Cancer

This article summarizes the key side effects associated with ADT for the treatment of prostate cancer and discusses strategies to optimize management.

A particular gatekeeper-the nuclear pore protein called POM121-traffics molecules that increase tumor aggressiveness in prostate cancer.

Small-cell neuroendocrine disease associated with prostate cancer treatment appears to be more common than previously believed.

A 62-year-old man with prostate adenocarcinoma elected to proceed with radical prostatectomy as definitive management. After his pathology report showed stage IIIB disease, he elected for observation. What happened next?

DNA and RNA sequencing results suggest prostate cancer treatment “involving inhibition of CDK12 and immune checkpoint blockade,” a U Michigan team said.

A large genomic analysis identified more than 60 new prostate cancer susceptibility loci, including one locus significantly associated with early onset.

A multicenter, international phase II study found higher-dose and extended-dose therapy with Ra-223 did not improve survival or pain scores.

Here we focus on alternative methods of harnessing both adaptive and innate antitumor immunity to target prostate cancer cells, and look ahead to provide a perspective on how this growing collection of immunotherapeutic approaches may ultimately be combined to target prostate cancer from a variety of angles.

The combination of the PARP inhibitor olaparib and abiraterone offered improved efficacy in patients with metastatic castration-resistant prostate cancer, but at what cost?

In SPCG-13, adjuvant docetaxel without prednisone did not impact biochemical DFS in intermediate- or high-risk disease treated with radical RT with ADT.

OS with the PSA-targeted, poxvirus-based cancer vaccine was no better than placebo, and increased survival was attributed to better standard of care.

Current smokers at the time of primary treatment for localized prostate cancer have a higher risk of negative outcomes, including recurrence, metastasis, and mortality.

USPSTF Vice-Chair Alex Krist and prostate cancer specialist David Penson shared perspectives on USPSTF’s updated prostate cancer screening recommendation.

In the PROPHECY study, men with mCRPC and AR-V7–positive CTCs had only a 0% to 11% probability of benefit from abiraterone or enzalutamide.

In AFT-30, increased frequency of PSA screening for localized prostate cancer did not boost survival, regardless of primary treatment or disease risk.

In the Abi Race study, response to abiraterone was greater and longer lasting in black men with prostate cancer, compared with white men.

Salvage cryoablation following local recurrence post radiation may be a safe way to avoid or delay initiation of hormone deprivation therapy.

A new analysis of PROSPER, presented at AUA 2018, suggests enzalutamide plus ADT may be superior to ADT alone in nonmetastatic CRPC.

A 65-year-old man presented with locally advanced, high-risk prostate cancer. His medical history was remarkable for type 2 diabetes mellitus, and he was an active smoker with a 27 pack-year history.

Chemotherapy is the best option for the initial management of metastatic prostate cancer.

Abiraterone has become the first-choice treatment for men with metastatic prostate cancer.

The US Preventive Services Task Force issued a final recommendation on prostate cancer screening, including that men aged 55 to 69 years should make an individual decision on whether or not to be screened.

An at-home online survey was found to be a reasonably accurate way to collect patient comorbidities prior to a physician visit in patients with prostate cancer.

In this podcast, Dr. Emmanuel Antonarakis discusses his novel clinical trial evaluating PARP inhibitors in high-risk and biochemically recurrent prostate cancer.

A study found some mutations that are already targeted by approved or investigational drugs for prostate cancer, along with dozens of targets that should be considered as candidates for future trials.

In this video, Dr. Judd Moul discusses disparities in prostate cancer screening among African-American men, and the need for more research in this area.

Combining mitoxantrone and prednisone with adjuvant androgen deprivation therapy failed to improve overall survival over ADT alone in patients with high-risk prostate cancer.

Increases in resource use were not associated with improved survival or quality of care for patients with metastatic prostate cancer, but were associated with higher healthcare costs.

Proton radiation therapy offers some reduced toxicity over IMRT in patients under the age of 65 with prostate cancer, but its cost is nearly double.

During the NCCN Annual Conference in Orlando, Dr. Peter Carroll from UCSF discussed the evolution of screening tests for prostate cancer.